Our unique approach to identifying disease signatures and developing diagnostics has three powerful components: population-scale serum samples, proprietary analytical technologies, and deidentified electronic health records that correspond with the serum samples. We have applied our technology in our Israeli multi-OMICS serum screening study to create the world’s largest and most comprehensive liquid-chromatography mass-spectrometry (LC-MS) metabolomics dataset. We are also expanding our datasets in lipidomics and proteomics.
Our high-throughput cost-effective multi-omics approach utilizes LC-MS to evaluate tens of thousands of biomarker molecules per sample, in a matter of minutes.
Through unique partnerships, including with a leading Israeli HMO serving millions of people, we receive de-identified samples daily for multi-OMICS analysis.
Serum samples are associated with de-identified prospective EHR data, supporting the development of novel diagnostic signatures for diverse diseases.